MaxCyte to Present Scalable Clinical and Commercial Manufacturing Technology for Cell-based and Viral-based Vaccines

    GAITHERSBURG, Md., July 16 /EMWNews/ -- MaxCyte, Inc., a

clinical-stage therapeutics company and pioneer in clinical scale,

non-viral cell loading systems, announces that Madhusudan V. Peshwa, Ph.D.,

Vice President Research and Development at MaxCyte, will present on

Thursday, July 17, 2008 at 4:40PM EDT at IBC's Next Generation Vaccines

Conference at Gaylord National Resort & Convention Center in National

Harbor, MD. Dr. Peshwa's presentation is entitled, "Scaleable Clinical and

Commercial Manufacturing Technology for Next Generation Vaccines" and will

discuss how MaxCyte's proprietary technology, which is currently being

employed in multiple clinical trials, solves the key issues of:

scalability, reproducibility, and commercial feasibility, while having a

well accepted regulatory path as well as the ability to improve upon

product titer and functional activity. Dr. Peshwa will discuss MaxCyte's

validated, regulatory-compliant technology in the context of a

manufacturing platform enabling rapid development of robust, scalable cGMP

production methods for vaccines, VLPs and viral vectors using various

flexible, single-use disposable configurations.

    About MaxCyte



    MaxCyte is a clinical-stage cell therapeutics company with a rapidly

growing pipeline of product development partnerships in cell-based

therapies. The Company's proprietary, non-viral, ex vivo cell loading

technology provides safety, scalability and reproducibility capabilities

which are fundamental to commercializing successful cell-based therapies.

MaxCyte has demonstrated the value of its versatile technology in partnered

therapeutic programs in oncology, pulmonary, metabolic and infectious

diseases as well as in development collaborations with leading researchers.

Current clinical programs with MaxCyte-engineered cells include: a Phase

IIa clinical study for treatment of chronic lymphocytic leukemia (CLL) and

a Phase IIa study using engineered stem cells for the treatment of primary

Pulmonary Arterial Hypertension (PAH). MaxCyte has recently partnered with

Medinet (JP) to commercialize a cell based therapy to be launched in 2008.

In addition, there are advanced preclinical programs in oncology and

regenerative medicine. More than 16 commercial and academic partners are

currently using the MaxCyte technology. The MaxCyte system has an FDA

Master File in place at the Center for Biologics Evaluation and Research

(CBER).



    For more information, visit http://www.maxcyte.com.